ABSTRACT:

Psoriasis is a common condition, affecting approximately 3-7% of the population in Western countries. It does not only affect the skin, as the buildup of skin cells can also result in the development of psoriatic arthritis that progresses to joint destruction. It is a chronic condition affecting over 60 million people worldwide. The incidence of psoriasis varies globally, with some countries reporting rates as low as 0.1% and others as high as 11.8%. This review discusses in detail the different aspects related to the epidemiology, etiology, and therapeutic approaches of psoriasis.

KEYWORDS:

Epidemiology, Etiology, Therapeutic Approaches, Psoriasis

REFERENCES :

1) Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005). Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity. ncbi.nlm.nih.gov
2) Belge, K., Brück, J., & Ghoreschi, K. (2014). Advances in treating psoriasis. ncbi.nlm.nih.gov 
3) Brajac, I. & Gruber, F. (2012). History of Psoriasis. [PDF]
4) Burden-Teh, E., S. Thomas, K., Ratib, S., J.C. Grindlay, D., Adaji, E., & Murphy, R. (2016). The epidemiology of childhood psoriasis: a scoping review. [PDF]
5) C. Cather, J. & J. Crowley, J. (2014). Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. ncbi.nlm.nih.gov
6) Chandran, V. (2010). Genetics Of Psoriasis And Psoriatic Arthritis. ncbi.nlm.nih.gov
7) Codrut Nicolescu, A., Ionescu, M. A., Magdalena Constantin, M., Ancuta, I., Ionescu, S., Niculet, E., Laurentiu Tatu, A., Zirpel, H., & Thaçi, D. (2022). Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. ncbi.nlm.nih.gov
8) Connor, J. C., Liu, V., & G. Fiedorowicz, J. (2015). Exploring the Physiological Link between Psoriasis and Mood Disorders. ncbi.nlm.nih.gov
9) Dhabale, A. & Nagpure, S. (2022). Types of Psoriasis and Their Effects on the Immune System. ncbi.nlm.nih.gov
10) Di Cesare, A., Ricceri, F., Rosi, E., Thais Fastame, M., & Prignano, F. (2022). Therapy of PsO in Special Subsets of Patients. ncbi.nlm.nih.gov
11) Drakos, A., Torres, T., & Vender, R. (2024). Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. ncbi.nlm.nih.gov
12) Elena Branisteanu, D., Cojocaru, C., Diaconu, R., Andrese Porumb, E., Iuliana Alexa, A., Codrut Nicolescu, A., Brihan, I., Margareta Bogdanici, C., Branisteanu, G., Dimitriu, A., Zemba, M., Anton, N., Paula Toader, M., Grechin, A., & Constantin Branisteanu, D. (2022). Update on the etiopathogenesis of psoriasis (Review). ncbi.nlm.nih.gov
13) Gaspari, A. & Tyring, S. (2015). New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. ncbi.nlm.nih.gov
14) Ghafel, N. Y. (2021) The relationship between the level of vitamin C and psoriasis. Al-Kufa University Journal for Biology, 13(2):8-21.
15) Gupta, A. M., K. Gupta, A., & F. Haberman, H. (1987). Psoriasis and psychiatry: An update. [PDF]
16) Hu, P., Wang, M., Gao, H., Zheng, A., Li, J., Mu, D., & Tong, J. (2021). The Role of Helper T Cells in Psoriasis. ncbi.nlm.nih.gov
17) Imafuku, S., Zheng, M., Tada, Y., Zhang, X., Theng, C., Thevarajah, S., Zhao, Y., & Jun Song, H. (2018). Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. ncbi.nlm.nih.gov
18) Jankowiak, B., Kowalewska, B., Krajewska-Kułak, E., & F. Khvorik, D. (2020). Stigmatization and Quality of Life in Patients with Psoriasis. ncbi.nlm.nih.gov
19) Kivelevitch, D., Mansouri, B., & Menter, A. (2014). Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. ncbi.nlm.nih.gov
20) Kowalska-Kępczyńska, A., Mleczko, M., Domerecka, W., Mazurek, M., Krasowska, D., Małecka-Massalska, T., & Donica, H. (2021). Extended Inflammation Parameters (EIP) as Markers of Immune System Cell Activation in Psoriasis. ncbi.nlm.nih.gov
21) Lee, H. J. & Kim, M. (2023). Challenges and Future Trends in the Treatment of Psoriasis. ncbi.nlm.nih.gov
22) Lee, S. R., Kim, S., Park, C. E., Lee, J. H., & Lee, D. H. (2019). Effect of Korean medicine as add-on therapy to phototherapy for psoriasis: Two case reports. ncbi.nlm.nih.gov
23) Li, Q. & Jiang, Y. (2022). Study on the Correlation between Morphology and Distribution of Common Psoriasis Lesions. ncbi.nlm.nih.gov
24) Mahé, E. (2020). Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives. ncbi.nlm.nih.gov
25) Marek-Jozefowicz, L., Czajkowski, R., Borkowska, A., Nedoszytko, B., A. Żmijewski, M., J. Cubała, W., & T. Slominski, A. (2022). The Brain–Skin Axis in Psoriasis—Psychological, Psychiatric, Hormonal, and Dermatological Aspects. ncbi.nlm.nih.gov
26) Martins, M. A., Ascenso, A., M. Ribeiro, H., & Marto, J. (2020). The Brain–Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System. ncbi.nlm.nih.gov
27) Mateu-Arrom, L. & Puig, L. (2023). Genetic and Epigenetic Mechanisms of Psoriasis. ncbi.nlm.nih.gov
28) Nedoszytko, B., Szczerkowska-Dobosz, A., Stawczyk-Macieja, M., Owczarczyk-Saczonek, A., Reich, A., Bartosiñska, J., Batycka-Baran, A., Czajkowski, R., T. Dobrucki, I., W. Dobrucki, L., Górecka-Sokołowska, M., Janaszak-Jasiecka, A., Kalinowski, L., Krasowska, D., Purzycka-Bohdan, D., Radulska, A., Reszka, E., Samotij, D., Sobalska-Kwapis, M., Słominski, A., Słominski, R., Strapagiel, D., Szczêch, J., Żmijewski, M., & J. Nowicki, R. (2020). Pathogenesis of psoriasis in the “omic” era. Part II. Genetic, genomic and epigenetic changes in psoriasis. ncbi.nlm.nih.gov
29) Parisi, R., Y K Iskandar, I., Kontopantelis, E., Augustin, M., E M Griffiths, C., & M Ashcroft, D. (2020). National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. ncbi.nlm.nih.gov
30) Patel, U N., Felix, K., Reimer, D., & R Feldman, S. (2017). Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. ncbi.nlm.nih.gov
31) Peng, C., Xu, X., Chen, W., Li, X., Yi, X., Ding, Y., Yu, N., & Lu, J. (2021). Epidemiological Variations in the Global Burden of Psoriasis, an Analysis With Trends From 1990 to 2017. ncbi.nlm.nih.gov
32) Rønholt, K. & Iversen, L. (2017). Old and New Biological Therapies for Psoriasis. ncbi.nlm.nih.gov
33) Sarac, G., Tulay Koca, T., & Baglan, T. (2016). A brief summary of clinical types of psoriasis. ncbi.nlm.nih.gov
34) Singh, K. R., M Lee, K., Ucmak, D., Brodsky, M., Atanelov, Z., Farahnik, B., Abrouk, M., Nakamura, M., Hao Zhu, T., & Liao, W. (2016). Erythrodermic psoriasis: pathophysiology and current treatment perspectives. ncbi.nlm.nih.gov
35) Tampa, M., Irina Mitran, M., Iulia Mitran, C., Matei, C., & Roxana Georgescu, S. (2024). Psoriasis: What Is New in Markers of Disease Severity?. ncbi.nlm.nih.gov
36) Thakur, V. & Mahajan, R. (2022). Novel Therapeutic Target(s) for Psoriatic Disease. ncbi.nlm.nih.gov
37) Tokuyama, M. & Mabuchi, T. (2020). New Treatment Addressing the Pathogenesis of Psoriasis. ncbi.nlm.nih.gov
38) Wnuk-Kłosiǹska, A., Bielanowska, E., Adamski, Z., Czajkowski, R., & Jenerowicz, D. (2021). The use of complementary and alternative medicine by patients suffering from psoriasis and psoriatic arthritis. ncbi.nlm.nih.gov
39) Yan, B. X., Chen, X. Y., Ye, L. R., Chen, J. Q., Zheng, M., & Man, X. Y. (2021). Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction. ncbi.nlm.nih.gov